Netherlands-incorporated Mylan (Nasdaq: MYL) and India’s Biocon (BSE: 532523) have launched Ogivri (trastuzumab-dkst) in the USA, a biosimilar to Roche’s (ROG: SIX) Herceptin.
Roche's super-blockbuster has led in the breast cancer space for a number of years, with consistent annual revenues of around $7 billion.
The drug has faced increasing competition, however, including from Pfizer’s (NYSE: PFE) Ibrance (palbociclib), which has picked up steam in recent years. Ibrance sales have grown to $4.1 billion in 2018.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze